# A Study to Evaluate Ampion in Patients With Prolonged Respiratory Symptoms Due to COVID-19 (Long COVID)

> **NCT04880161** · PHASE1 · COMPLETED · sponsor: **Ampio Pharmaceuticals. Inc.** · enrollment: 32 (actual)

## Conditions studied

- Covid19

## Interventions

- **BIOLOGICAL:** Ampion
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT04880161
- **Lead sponsor:** Ampio Pharmaceuticals. Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-07-26
- **Primary completion:** 2021-12-22
- **Final completion:** 2022-02-21
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2023-09-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04880161

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04880161, "A Study to Evaluate Ampion in Patients With Prolonged Respiratory Symptoms Due to COVID-19 (Long COVID)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04880161. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*